KY
KYMR.US Kymera Therapeutics Inc
- Market cap
- USD 10.9B
- P/E
- -
- P/B
- 6.75x
- ROE
- -21.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KYMR.US undervalued?
Graham numberThe Graham number of Kymera Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kymera Therapeutics Inc fundamental analysis
No fundamental analysis for Kymera Therapeutics Inc yet.
Kymera Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials f…
Full company profileKymera Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kymera Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 2.93M | 34.0M | 72.8M | 46.8M | 78.6M | 47.1M | 39.2M | 132M |
| Gross Profit | -205K | 2.11M | 34.0M | 72.8M | 46.8M | 78.6M | 47.1M | 39.2M | - |
| Operating Income | -21.5M | -42.2M | -46.3M | -101M | -161M | -166M | -262M | -349M | -409M |
| EBITDA | -21.2M | -40.4M | -43.7M | -97.6M | -152M | -143M | -216M | -303M | -342M |
| Net Income | -21.5M | -41.3M | -45.6M | -100M | -155M | -147M | -224M | -311M | -350M |
| EPS | -0.48 | -0.93 | -1.02 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | -3.50 |
| Balance Sheet | |||||||||
| Total Assets | 44.2M | 117M | 487M | 606M | 603M | 576M | 978M | 1.74B | 1.77B |
| Total Liabilities | 78.7M | 191M | 203M | 146M | 113M | 181M | 142M | 163M | 153M |
| Shareholders' Equity | -34.4M | -74.4M | 284M | 460M | 490M | 395M | 836M | 1.58B | 1.61B |
| Cash & Short-term Investments | 41.3M | 92.0M | 296M | 442M | 407M | 375M | 489M | 848M | 971M |
| Total Debt | 695K | 21.2M | 18.0M | 18.0M | 17.3M | 84.7M | 87.8M | 82.3M | 76.6M |
| Cash Flow | |||||||||
| Operating Cash Flow | -17.9M | 17.9M | 88.1M | -129M | -153M | -103M | -195M | -233M | -294M |
| Capital Expenditure | 1.36M | 532K | 9.10M | 1.60M | 2.84M | 34.5M | 12.8M | 1.45M | 1.63M |
| Free Cash Flow | -19.2M | 17.4M | 79.0M | -131M | -156M | -137M | -207M | -234M | -296M |
| Ratios | |||||||||
| ROE | - | - | -16.1% | -21.8% | -31.6% | -37.2% | -26.8% | -19.7% | -21.7% |
| ROA | -48.5% | -35.4% | -9.4% | -16.5% | -25.7% | -25.5% | -22.9% | -17.9% | -19.8% |
| Net Profit Margin | - | -1,407.4% | -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.4% | -264.1% |
| Debt to Equity | - | - | 0.06x | 0.04x | 0.04x | 0.21x | 0.11x | 0.05x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kymera Therapeutics Inc dividends
Kymera Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Who owns Kymera Therapeutics Inc
- Insiders 3.22%
- Institutions 96.78%
- Public & others 0.00%
- Shares outstanding 85.4M
- Free float 68.3M
Top funds holding KYMR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 2.24M | 2.63% | +0.39% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.10M | 2.46% | +0.30% | Sep 2026 |
| Vanguard Health Care Inv | 1.80M | 2.10% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 1.70M | 2.00% | -15.63% | Sep 2026 |
| iShares Russell 2000 ETF | 1.59M | 1.86% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.50M | 1.75% | -1.18% | Sep 2026 |
| American Funds SMALLCAP World A | 1.32M | 1.54% | -2.51% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.15M | 1.34% | +2.68% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 834K | 0.98% | -4.06% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 777K | 0.91% | -0.57% | Sep 2026 |
| T. Rowe Price Growth Stock | 687K | 0.80% | +14.00% | Sep 2026 |
| Fidelity Small Cap Index | 686K | 0.80% | +0.15% | Aug 2026 |
| Vanguard Explorer Inv | 681K | 0.80% | +3.39% | Sep 2026 |
| T. Rowe Price Health Sciences | 641K | 0.75% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 619K | 0.73% | +0.41% | Aug 2026 |
| T. Rowe Price All-Cap Opportunities Fund | 594K | 0.70% | -2.19% | Sep 2026 |
| iShares Biotechnology ETF | 581K | 0.68% | -0.35% | Oct 2026 |
| Fidelity Select Biotechnology | 556K | 0.65% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 554K | 0.65% | +0.40% | Aug 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 528K | 0.62% | -6.88% | Sep 2026 |
Top institutions holding KYMR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 12.3M | 14.47% | +5.55% | Jun 2026 |
| Baker Bros Advisors LP | 8.66M | 10.14% | 0.00% | Jun 2026 |
| venBio Select Advisor LLC | 7.47M | 8.76% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 7.11M | 8.33% | +17.36% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 6.26M | 7.33% | +14.50% | Jun 2026 |
| BlackRock Inc | 5.54M | 6.49% | +9.43% | Jun 2026 |
| Bvf Inc | 3.87M | 4.54% | -29.63% | Jun 2026 |
| Wellington Management Company LLP | 3.68M | 4.30% | -5.52% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.99M | 3.50% | +4.11% | Jun 2026 |
| Siren, L.L.C. | 2.94M | 3.44% | -7.88% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.93M | 3.43% | +1.81% | Jun 2026 |
| Atlas Venture Life Science Advisors, LLC | 2.85M | 3.34% | -37.80% | Jun 2026 |
| State Street Corp | 2.74M | 3.21% | +14.54% | Jun 2026 |
| Geode Capital Management, LLC | 1.82M | 2.13% | +10.39% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.19M | 1.39% | +33.65% | Jun 2026 |
| Capital Research Global Investors | 1.13M | 1.32% | -18.61% | Sep 2026 |
| UBS Group AG | 1.01M | 1.18% | -1.57% | Jun 2026 |
| AllianceBernstein L.P. | 982K | 1.15% | +10.53% | Jun 2026 |
| Driehaus Capital Management LLC | 919K | 1.08% | -11.92% | Jun 2026 |
| Merck & Co Inc | 772K | 0.90% | 0.00% | Jun 2026 |
Kymera Therapeutics Inc company profile
- Company name
- Kymera Therapeutics Inc
- Ticker
- KYMR.US
- Exchange
- USA Stocks
- Listed since
- Aug 21, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 285
- Fiscal year end
- December
- Address
- 500 North Beacon Street, Watertown, MA, United States, 02472
- Phone
- 857 285 5300
- Website
- kymeratx.com
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics Inc management
10- Dr. Nello Mainolfi M.D., Ph.D.Co-Founder, President, CEO & Director · born 1979
- Mr. Bruce N. Jacobs CFAChief Financial Officer
- Mr. Brian R. Adams J.D.Chief Legal Officer & Corporate Secretary · born 1974
- Dr. Jared A. Gollob M.D.Advisor · born 1965
- Mr. Noah Goodman M.B.A.Chief Business Officer · born 1987
- Ms. Justine E. KoenigsbergVice President of Investor Relations
- Dr. Neil Graham M.D., M.P.H., MBBSChief Development Officer · born 1959
- Mr. Brian Albarran M.B.A., Ph.D.SVP of Corporate Strategy
- Dr. Juliet Williams B.A Ph.D.Head of Research
- Dr. Jeremy G. Chadwick Ph.D.Advisor · born 1963